Daewoong 1Q26 Consolidated Sales KRW 492.7B, OP KRW 47.8B – Routine Quarterly Results

Daewoong (holding company) 1Q26 consolidated: revenue KRW 492.7B, operating profit KRW 47.8B, net profit KRW 53.3B.
Key sub Daewoong Pharmaceutical (52.65% stake): standalone revenue KRW 335.7B (+6.2% YoY), OP KRW 27.4B (-34.7% due to R&D rise).
Consolidated debt ratio 83.9%, net debt/equity 27.0% – healthy.
Capital KRW 29.1B, shares outstanding 58,141,980; treasury shares 16,105,105 (27.7%).
In 1Q sold 564,745 treasury shares to Jigu Holdings for partnership.
No new dividend decision; past dividend (200 won per share for FY2025) and charter change for dividend date separation.
Ongoing Meditox trade secret lawsuit (appeal); provision of KRW 56.8B.
Major products Nabota, Fexuprazan, Enavogliflozin under global licensing.
35 consolidated subsidiaries including HanAll Biopharma.